Abstract Library

#4499 Impact of early molecular tumour board inclusion on treatment outcomes in neuroendocrine neoplasms: A retrospective double-centre study

Introduction: The treatment of neuroendocrine neoplasms (NENs) is particularly challenging due to the limited availability of standard therapies. While personalised approaches are revolutionising many areas of oncology, their progress in the field of NENs has been comparatively slower. The integration of molecular tumour boards (MTBs) into clinical practice represents a major advance in oncology, even for rare entities such as NENs.

Conference:

Presenting Author: Klaas L

Authors: Barsch M, Graessel L, Metzger P, Klaas L, Schulz L,

Keywords: Neuroendocrine neoplasm, Molecular Tumour Board, personalised medicine, precision oncology, targeted therapy,

#4326 An evaluation of the methodological quality of published guidelines for the surgical treatment of pulmonary carcinoids

Introduction: Leading societies have established guidelines that vary significantly regarding recommendations for surgical management of pulmonary carcinoids (PC).

Conference:

Presenting Author: Bertolaccini L

Authors: Bertolaccini L, Bardoni C, Caffarena G, Chiari M, Diotti C,

Keywords: Neuroendocrine, lung cancer, surgery, AGREE 2, methodology, guidelines,

#4284 Malignant GEP-NET with CBD stricture and portal lymphadenopathy – A rare case report and review of literature

Introduction: Gastric neuroendocrine tumours (gNET) are neoplasms derived from enterochromaffin-like cells (ECL cells). A malignant gastrointestinal neuroectodermal tumour (GNET) is an extremely rare tumour with only less than 40 reported cases. They are rare lesions with indolent behaviour and neuroendocrine differentiation.

Conference:

Presenting Author: Farman A

Authors: Farman A, Raghavendra B, Subash K,

Keywords: carcinoid, gNET, GEP-NET, portal, CBD stricture, gastrectomy, lymphadenopathy,

#4162 Functioning neuroendocrine neoplasms: Symptomatic control with 177Lu-DOTATATE

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is recommended in unresectable and metastatic gastroenteropancreatic neuroendocrine neoplasms (NENs), however, recommendations for functioning NENs (F-NENs) are not well established. Besides PRRT impact in OS and PFS, real-life benefit in clinical control is also a relevant outcome, especially in F-NENs.

Conference:

Presenting Author: Santos A

Authors: Lopes-Pinto M, Silva D, Ribeiro S, Oliveira J, Ferreira G,

Keywords: neuroendocrine neoplasm, functioning neuroendocrine neoplasm, carcinoid syndrome, PRRT,

#4094 Peptide Receptor Radionuclide Therapy improves progression free and overall survival in patients who progress after resection of gastroenteropancreatic NETs

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) improves progression-free-survival (PFS) in advanced midgut neuroendocrine tumors (NETs). Whether PRRT specifically improves survival in surgically managed gastroenteropancreatic (GEP) NET with progression is unknown.

Conference:

Presenting Author: Howe J

Authors: Borbon L, Sherman S, Breheny P, Ear P, Menda Y,

Keywords: gastroenteropancreatic, resection, progression, PRRT, neuroendocrine tumor,